Article Text

PDF
Real costs of end-of-life drugs

Statistics from Altmetric.com

In January 2009, the National Institute for Health and Clinical Excellence (NICE) began a policy for valuing the use of drugs for extending life in people with a short life-expectancy above treatments for other purposes. This development arose from concerns that NICE had been denying patients life-extending treatments because they were too expensive; such drugs exceeded the Institute's quality-adjusted life years (QALY) threshold of £20,000–£30,000. However, the new policy also …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.